BeiGene
BGNE
#881
Rank
ยฃ16.89 B
Marketcap
ยฃ153.91
Share price
1.71%
Change (1 day)
-1.81%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (BGNE)

Earnings in 2024 (TTM): -ยฃ0.71 B

According to BeiGene 's latest financial reports the company's current earnings (TTM) are -ยฃ0.68 B. In 2023 the company made an earning of -ยฃ0.93 B an increase over its 2022 earnings that were of -ยฃ1.37 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) -ยฃ0.71 B-23.63%
2023 -ยฃ0.93 B-32.52%
2022 -ยฃ1.37 B24.39%
2021 -ยฃ1.1 B-13.21%
2020 -ยฃ1.27 B72.69%
2019 -ยฃ0.74 B36.01%
2018 -ยฃ0.54 B616.83%
2017 -ยฃ75.03 M-15.24%
2016 -ยฃ88.52 M107.91%
2015 -ยฃ42.58 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-ยฃ13.84 M-97.95%๐Ÿ‡บ๐Ÿ‡ธ USA
-ยฃ0.19 B-72.40%๐Ÿ‡บ๐Ÿ‡ธ USA